Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVO NASDAQ:GRCE NASDAQ:HOWL NASDAQ:NCNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$4.00+5.3%$4.03$3.51▼$13.13$37.04M-0.6371,267 shs23,495 shsGRCEGrace Therapeutics$2.26+0.4%$3.89$1.79▼$5.18$34.81M0.32561,562 shs107,974 shsHOWLWerewolf Therapeutics$0.69+11.6%$0.81$0.53▼$2.38$33.44M0.41425,021 shs1.76 million shsNCNANuCana$2.16+3.1%$1.95$1.33▼$40.00$8.97M2.1752,770 shs15,512 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed-1.91%+2.98%-1.04%-28.44%-57.06%GRCEGrace Therapeutics-5.06%+0.45%-32.43%-37.50%-25.50%HOWLWerewolf Therapeutics-4.64%-13.84%-38.00%+1.27%-32.75%NCNANuCana-5.43%-1.88%+1.95%-5.86%-96.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$4.00+5.3%$4.03$3.51▼$13.13$37.04M-0.6371,267 shs23,495 shsGRCEGrace Therapeutics$2.26+0.4%$3.89$1.79▼$5.18$34.81M0.32561,562 shs107,974 shsHOWLWerewolf Therapeutics$0.69+11.6%$0.81$0.53▼$2.38$33.44M0.41425,021 shs1.76 million shsNCNANuCana$2.16+3.1%$1.95$1.33▼$40.00$8.97M2.1752,770 shs15,512 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed-1.91%+2.98%-1.04%-28.44%-57.06%GRCEGrace Therapeutics-5.06%+0.45%-32.43%-37.50%-25.50%HOWLWerewolf Therapeutics-4.64%-13.84%-38.00%+1.27%-32.75%NCNANuCana-5.43%-1.88%+1.95%-5.86%-96.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVOCervoMed 2.63Moderate Buy$23.00475.00% UpsideGRCEGrace Therapeutics 2.00Hold$6.00165.60% UpsideHOWLWerewolf Therapeutics 2.14Hold$3.75441.91% UpsideNCNANuCana 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest NCNA, CRVO, HOWL, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/23/2026CRVOCervoMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/22/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.004/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NCNANuCana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRVOCervoMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.003/18/2026CRVOCervoMed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $11.003/18/2026CRVOCervoMed Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVOCervoMed$4.01M9.24N/AN/A$1.97 per share2.03GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/AHOWLWerewolf Therapeutics$1.88M17.89N/AN/A$0.51 per share1.36NCNANuCanaN/AN/AN/AN/A$7.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVOCervoMed-$26.97M-$2.98N/AN/AN/A-672.80%-96.04%-82.88%5/11/2026 (Estimated)GRCEGrace Therapeutics-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)HOWLWerewolf Therapeutics-$60.82M-$1.36N/AN/AN/AN/A-158.82%-69.75%N/ANCNANuCana-$38.71M-$127.73N/AN/AN/AN/A-189.94%-130.93%5/14/2026 (Estimated)Latest NCNA, CRVO, HOWL, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026N/ANCNANuCana-$2.6440N/AN/AN/AN/AN/A5/11/2026Q1 2026CRVOCervoMed-$0.7875N/AN/AN/A$0.07 millionN/A5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/A3/13/2026Q4 2025CRVOCervoMed-$0.79-$0.88-$0.09-$0.88$0.84 million$0.01 million2/12/2026Q3 2026GRCEGrace Therapeutics-$0.09-$0.14-$0.05-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVOCervoMedN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVOCervoMedN/A4.914.91GRCEGrace TherapeuticsN/A14.9614.96HOWLWerewolf TherapeuticsN/A1.621.62NCNANuCanaN/A5.605.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVOCervoMed25.15%GRCEGrace Therapeutics6.08%HOWLWerewolf Therapeutics64.84%NCNANuCana44.00%Insider OwnershipCompanyInsider OwnershipCRVOCervoMed35.40%GRCEGrace Therapeutics11.10%HOWLWerewolf Therapeutics23.60%NCNANuCana31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVOCervoMed49.26 million5.98 millionNot OptionableGRCEGrace TherapeuticsN/A15.47 million13.76 millionN/AHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableNCNANuCana304.16 million2.86 millionNot OptionableNCNA, CRVO, HOWL, and GRCE HeadlinesRecent News About These CompaniesNuCana (NCNA) to Release Quarterly Earnings on ThursdayMay 7 at 2:28 AM | americanbankingnews.comNuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029March 22, 2026 | theglobeandmail.comNuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business UpdateMarch 19, 2026 | globenewswire.comNuCana plc: NuCana Appoints Theresa Bruce as Chief Operating OfficerJanuary 6, 2026 | finanznachrichten.deNuCana appoints Bruce as COOJanuary 6, 2026 | msn.comNuCana Appoints Theresa Bruce as Chief Operating OfficerJanuary 6, 2026 | globenewswire.comNuCana announces return of CEO Hugh S Griffith following health leaveDecember 17, 2025 | msn.comNuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 ...December 10, 2025 | bakersfield.comBNuCana presents latest clinical data at ESMO 2025 on NUC-7738December 10, 2025 | msn.comNuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant MelanomaDecember 10, 2025 | globenewswire.comNuCana Reports Q3 2025 Financial Results and Board ResignationNovember 13, 2025 | msn.comNuCana plc: NuCana Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 13, 2025 | finanznachrichten.deNuCana Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 13, 2025 | globenewswire.comNuCana stock rises after securing key patent in China for cancer drugNovember 5, 2025 | za.investing.comNuCana Shares Climb After Securing Key Chinese Patent for Cancer Drug NUC-7738November 5, 2025 | msn.comNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in ChinaNovember 5, 2025 | globenewswire.comNuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitorsOctober 19, 2025 | msn.comNuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ...October 18, 2025 | finance.yahoo.comNuCana announces publication of new data for NUC-3373October 14, 2025 | msn.comNuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 TherapyOctober 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, CRVO, HOWL, and GRCE Company DescriptionsCervoMed NASDAQ:CRVO$4.00 +0.20 (+5.26%) As of 12:05 PM Eastern This is a fair market value price provided by Massive. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Grace Therapeutics NASDAQ:GRCE$2.26 +0.01 (+0.40%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Werewolf Therapeutics NASDAQ:HOWL$0.69 +0.07 (+11.61%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.NuCana NASDAQ:NCNA$2.15 +0.07 (+3.11%) As of 12:05 PM Eastern This is a fair market value price provided by Massive. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
